[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"usual-interstitial-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:usual-interstitial-pneumonia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637681","a-comparison-of-a-medication-adherence-platform-fortiskap-vs-usual-care-in-subjects-on-oral-medications-for-the-treatment-of-interstitial-lung-disease-sarcoid-and-pulmonary-hypertension-100637681",false,"NCT07613216","A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension","Inclusion Criteria:\n\n1. 21 years of age or older at time of enrollment\n2. Primary diagnosis of interstitial lung disease (including sarcoidosis) AND\u002FOR pulmonary hypertension\n3. Currently managing their oral medications independently (i.e., without requiring caregiver administration)\n4. At least one oral medication with a primary indication for treatment of ILD or PH already in use, or planned for initiation with insurance approval secured, at the time of enrollment\n5. 6-Minute Walk Test (6MWT) scheduled within the next 30 days or performed within the past 30 days\n6. For ILD subjects: FVC and\u002For DLCO scheduled within the next 30 days or performed within the past 90 days\n7. For PH subjects: Cardiac echocardiography scheduled within the next 30 days or performed within the past 90 days\n8. Daily access to a smartphone compatible with the FORTISKAP™ companion application\n9. Proficient in English\n\nExclusion Criteria:\n\nFailure to meet any one of the above inclusion criteria","ALL","21 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.",[23,24,25,26],"Idiopathic Pulmonary Fibrosis (IPF)","Sarcoidosis Lung","Pulmonary Hypertension","Usual Interstitial Pneumonia",[28,29,30,31],"medication adherence","Interstitial Lung Disease","nintedanib","pirfenidone","NOT_YET_RECRUITING","2026-05-26",{"date":35,"type":36},"2026-05-29","ACTUAL",{"date":38,"type":19},"2026-07",{"date":40,"type":19},"2027-08",{"name":42,"class":43},"Cosmos Rx, Inc","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":20,"phases":4,"briefSummary":58,"conditions":59,"keywords":67,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":44},"100439826","ild-sards-registry-and-biorepository-100439826","NCT05007340","ILD-SARDs Registry and Biorepository","Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository","ILD-SARDs","Inclusion Criteria:\n\n1. Must be aged 18 years or older\n2. Diagnosis of ILD as confirmed by a chest CT\n3. Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD\n4. Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures.\n\nExclusion Criteria:\n\nN\u002FA",true,"18 Years",{"count":56,"type":19},252,"5 Years","A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs.\n\nThe purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.",[29,60,61,62,63,64,65,26,66],"Systemic Autoimmune Disease","Rheumatic Diseases","Rheumatic Arthritis","Systemic Sclerosis","Autoimmune Myositis","Systemic Lupus Erythematosus","Nonspecific Interstitial Pneumonia",[29,60,61,62,63,64,65,26,66],"RECRUITING","2021-09-01",{"date":71,"type":36},"2021-09-09",{"date":73,"type":36},"2021-08-24",{"date":75,"type":19},"2026-08",{"name":77,"class":78},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER"]